nach oben

Erschienen in:

01.12.2012 | original article

Non-dipping nocturnal blood pressure in psoriasis vulgaris

verfasst von: Ahmet Bacaksiz, MD, Mehmet Akif Vatankulu, MD, Osman Sonmez, MD, Ercan Erdogan, MD, Abdurrahman Tasal, MD, Murat Turfan, MD, Gokhan Ertas, MD, Emrah Sevgili, MD, Didem Dizman, MD, Prof. Nahide Onsun

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2012

Einloggen, um Zugang zu erhalten

Summary

Background

Psoriasis vulgaris is one of the most prevalent chronic, inflammatory skin disorders. Patients with psoriasis carry an excess risk of hypertension and adverse cardiovascular (CV) events. Blood pressure (BP) has a circadian rhythm characterised with lower values at night. A blunted nocturnal BP decline defined as non-dipping accelerates the development of hypertension and CV diseases. The aim of this study is to evaluate circadian variation of blood pressure in normotensive middle-aged patients with psoriasis vulgaris.

Methods

Seventy adult patients with psoriasis vulgaris (group 1) and 70 age and sex-matched healthy individuals (group 2) were included in the study. Ambulatory BP monitoring was performed in all participants over a 24-h period. Non-dippers are defined as those who show a reduction in BP of less than 10 % between the average day and night systolic BP.

Results

Although mean 24-h BPs were similar in both groups, night-time BPs were significantly higher in psoriatic patients (115.1 ± 7.7 vs. 109.9 ± 6.0 mmHg and 72.1 ± 7.0 vs. 67.6 ± 5.5 mmHg, respectively; p < 0.05). The non-dipping pattern of BP changes was significantly more common in patients with psoriasis vulgaris compared with the control group (65.9 vs. 34.1 %, p < 0.01). Psoriasis severity and BMI are independent predictors of impaired nocturnal BP regulation.

Conclusions

Patients with psoriasis vulgaris had increased nocturnal BP and heart rate. This is the first study to demonstrate a blunted nocturnal BP decrease in normotensive patients with psoriasis.

Vorheriger Artikel Cholesterol metabolism in acute upper gastrointestinal bleeding, preliminary observations

Nächster Artikel Temporal factors in violence related injuries—An 11 year trend analysis of violence-related injuries from a Swiss Emergency Department

Soylu A, Yazici M, Duzenli MA, Tokac M, Ozdemir K, Gok H. Relation between abnormalities in circadian blood pressure rhythm and target organ damage in normotensives. Circ J. 2009;73(5):899–904.PubMedCrossRef

Li L, Soonthornpun S, Chongsuvivatwong V. Association between circadian rhythm of blood pressure and glucose tolerance status in normotensive, non-diabetic subjects. Diabetes Res Clin Pract. 2008;82(3):359–63.PubMedCrossRef

Sayk F, Becker C, Teckentrup C, Fehm HL, Struck J, Wellhoener JP, et al. To dip or not to dip: on the physiology of blood pressure decrease during nocturnal sleep in healthy humans. Hypertension. 2007;49(5):1070–6.PubMedCrossRef

Cuspidi C, Meani S, Valerio C, Negri F, Sala C, Maisaidi M, et al. Body mass index, nocturnal fall in blood pressure and organ damage in untreated essential hypertensive patients. Blood Press Monit. 2008;13(6):318–24.PubMedCrossRef

Kawano Y, Horio T, Matayoshi T, Kamide K. Masked hypertension: subtypes and target organ damage. Clin Exp Hypertens. 2008;30(3):289–96.PubMedCrossRef

Viera AJ, Zhu S, Hinderliter AL, Shimbo D, Person SD, Jacobs DR Jr. Diurnal blood pressure pattern and development of prehypertension or hypertension in young adults: the CARDIA study. J Am Soc Hypertens. 2011;5(1):48–55.PubMedCrossRef

Hermida RC, Chayán L, Ayala DE, Mojón A, Domínguez MJ, Fontao MJ, et al. Association of metabolic syndrome and blood pressure nondipping profile in untreated hypertension. Am J Hypertens. 2009;22(3):307–13.PubMedCrossRef

Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens. 2006;19(3):243–50.PubMedCrossRef

Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens. 1997;10(11):1201–7.PubMedCrossRef

10.

Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–912.PubMedCrossRef

11.

Rosa DJ, Machado RF, Matias FA, Cedrim SD, Noronha FL, Gaburri D, et al. Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. J Eur Acad Dermatol Venereol. 2012;26(3):348–53.PubMedCrossRef

12.

Markuszeski L, Bissinger A, Janusz I, Narbutt J, Jedrzejowska AS, Zalewska A. Heart rate and arrhythmia in patients with psoriasis vulgaris. Arch Med Res. 2007;38(1):64–9.PubMedCrossRef

13.

Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012;33(16):2054–64.PubMedCrossRef

14.

Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–8.PubMedCrossRef

15.

Zindancı I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, et al. Prevalence of metabolic syndrome in patients with psoriasis. ScientificWorldJournal. 2012;2012:312463.PubMed

16.

Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10(2):7.PubMed

17.

Amornpinyokeit N, Asawanonda P. 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Photomed. 2006;22:285–9.PubMedCrossRef

18.

Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206–12.PubMedCrossRef

19.

Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.PubMedCrossRef

20.

Madin K, Iqbal P. Twenty four hour ambulatory blood pressure monitoring: a new tool for determining cardiovascular prognosis. Postgrad Med J. 2006;82(971):548–51.PubMedCrossRef

21.

Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60.PubMedCrossRef

22.

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.PubMed

23.

Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis. 2010;55(3):590–8.PubMedCrossRef

24.

Pierdomenico SD, Cuccurullo F. Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. Blood Press Monit. 2010;15(1):1–7.PubMedCrossRef

25.

O’Brien E. Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J Intern Med. 2011;269(5):478–95.CrossRef

26.

Liu T, Li G. Psoriasis, inflammation, and atrial fibrillation. Am J Cardiol. 2008;102(5):647.PubMedCrossRef

27.

Flammer AJ, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? Eur Heart J. 2012;33(16):1989–91.PubMedCrossRef

28.

Rico T, Marchione R, Kirsner RS. Vascular disease in psoriasis. J Invest Dermatol. 2009;129(10):2327.PubMedCrossRef

29.

Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, et al. Integrated approach to comorbidity in patients with psoriasis. Actas Dermosifiliogr. 2012;103(Suppl 1):1–64.PubMed

30.

Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PLoS One. 2011;6(3):e18227.PubMedCrossRef

31.

Halıgür BD, Cicek D, Bulut S, Berilgen MS. The investigation of autonomic functions in patients with psoriasis. Int J Dermatol. 2012;51(5):557–63. doi:10.1111/j.1365-4632.2011.05111.x.PubMedCrossRef

32.

Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40(2):199–205.PubMed

33.

Boehncke WH, Boehncke S. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. G Ital Dermatol Venereol. 2008;143(5):307–13.PubMed

34.

Enany B, El Zohiery AK, Elhilaly R, Badr T. Carotid intima-media thickness and serum leptin in psoriasis. Herz. 2012;37(5)527–33.PubMedCrossRef

35.

Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, Girolomoni G. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology. 2009;218(2):110–3.PubMedCrossRef

36.

Birkenhäger AM, Van Den Meiracker AH. Causes and consequences of a non-dipping blood pressure profile. Neth J Med. 2007;65(4):127–31.PubMed

37.

Pickering TG, Kario K. Nocturnal non-dipping: what does it augur? Curr Opin Nephrol Hypertens. 2001;10(5):611–6.PubMedCrossRef

38.

Minamisawa K, Tochikubo O, Ishii M. Systemic hemodynamics during sleep in young or middle-aged and elderly patients with essential hypertension. Hypertension. 1994;23(2):167–73.PubMedCrossRef

39.

Ulusoy RE, Karabudak O, Yokusoglu M, Kilicaslan F, Kirilmaz A, Cebeci BS. Noninvasive assessment of impaired endothelial function in psoriasis. Rheumatol Int. 2010;30(4):479–83.PubMedCrossRef

40.

41.

Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194–9.PubMedCrossRef

42.

Ryan MJ. The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R1258–67.PubMedCrossRef

43.

Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med. 2006;18(3):415–23.PubMed

44.

Rihácek I, Frána P, Soucek M, Plachý M, Kianicka B. The diurnal variability of blood pressure in patients with hypertension and rheumatoid arthritis. Vnitr Lek. 2009;55(2):111–6.PubMed

Titel: Non-dipping nocturnal blood pressure in psoriasis vulgaris
verfasst von: Ahmet Bacaksiz, MD
Mehmet Akif Vatankulu, MD
Osman Sonmez, MD
Ercan Erdogan, MD
Abdurrahman Tasal, MD
Murat Turfan, MD
Gokhan Ertas, MD
Emrah Sevgili, MD
Didem Dizman, MD
Prof. Nahide Onsun
Publikationsdatum: 01.12.2012
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 23-24/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-012-0294-y

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 23-24/2012

Conventional laparoscopy vs. single port surgery from a patient’s point of view: influence of demographics and body mass index

Cholesterol metabolism in acute upper gastrointestinal bleeding, preliminary observations

Clinically symptomatic heterozygous carnitine palmitoyltransferase II (CPT II) deficiency

Temporal factors in violence related injuries—An 11 year trend analysis of violence-related injuries from a Swiss Emergency Department

Cardiovascular MR imaging findings of total anomalous pulmonary venous connection to the portal vein in a patient with right atrial isomerism

Therapeutic hypothermia for severe adult Herpes simplex virus encephalitis